Owners, management and financials
CVR: 39981610
Secondary names: Stem Therapy ApS, StemCell Evolution ApS, StemCell Dynamics ApS
Previous names: Regenerative Therapeutics IVS
DKK -5,780,568
Gross profit
Net result: DKK -21,221,120
SEIER CAPITAL A/S (5-9,99%), ANDRÉ ROGACZEWSKI HOLDING II ApS (33,33-49,99%)
1 more
CVR · view owners
Søren Paludan Sheikh
Board: Olav Hellebø (chair) and 4 members
CVR · view management
Active
Founded 28 October 2018
CVR · view overview
9 employees
Annual report 2025 · average
Owner registered: SEIER CAPITAL A/S
CVR · 29/06/2026
View the full event history
Blue Cell Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Regenerative Therapeutics IVS. The management consists of Søren Paludan Sheikh. The board consists of Olav Hellebø (chair), Anella Rogaczewski, Michael Ulveman and Ole Vahlgren. The company is owned by SEIER CAPITAL A/S, ANDRÉ ROGACZEWSKI HOLDING II ApS and SPSheikh Holding ApS. According to the 2025 annual report, the company had an average of 9 employees. In 2025, the company reported a gross profit of DKK -5,780,568 and a net result of DKK -21,221,120 compared with DKK -15,189,850 the year before. Equity in the 2025 report amounted to DKK -8,126,690.
Selskabets formål er at drive virksomhed med udvikling, behandling og kommercialisering af stamceller og hermed efter ledelsens skøn beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -5.8 mio. | -21.2 mio. | 4.8 mio. | -8.1 mio. | 9 | |
| 202401/01/2024 – 31/12/2024 | -3.1 mio. | -15.2 mio. | 14.1 mio. | 13.1 mio. | 12 | |
| 202301/01/2023 – 31/12/2023 | -742 t. | -15.3 mio. | 10.2 mio. | 8.4 mio. | 14 | |
| 202201/01/2022 – 31/12/2022 | 852 t. | -12.6 mio. | 10.6 mio. | 9.9 mio. | 12 | |
| 202101/01/2021 – 31/12/2021 | -844 t. | -14.2 mio. | 14 mio. | 12.5 mio. | 7 | |
| 202001/01/2020 – 31/12/2020 | -2.9 mio. | -14 mio. | 13.5 mio. | 9.8 mio. | 2 |
Compared to 1.040 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of Blue Cell Therapeutics ApS is 39981610.
Blue Cell Therapeutics ApS is owned by SEIER CAPITAL A/S, ANDRÉ ROGACZEWSKI HOLDING II ApS and SPSheikh Holding ApS.
The management of Blue Cell Therapeutics ApS consists of Søren Paludan Sheikh.
The board of Blue Cell Therapeutics ApS consists of Olav Hellebø, Anella Rogaczewski and Michael Ulveman, with Olav Hellebø as chair.
In 2025, Blue Cell Therapeutics ApS reported a gross profit of DKK -5,780,568.
Blue Cell Therapeutics ApS had an average of 9 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Blue Cell Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -5,780,568, and the net result was DKK -21,221,120.
As of June 29, 2026, SEIER CAPITAL A/S is registered as an owner of Blue Cell Therapeutics ApS with an ownership share of 5%.
As of June 29, 2026, ANDRÉ ROGACZEWSKI HOLDING II ApS is registered as an owner of Blue Cell Therapeutics ApS with an ownership share of 33%.
As of June 29, 2026, SPSheikh Holding ApS is registered as an owner of Blue Cell Therapeutics ApS with an ownership share of 33%.
As of August 8, 2025, Ole Vahlgren has joined the board of directors of Blue Cell Therapeutics ApS.
As of August 8, 2025, Olav Hellebø has joined the board of directors of Blue Cell Therapeutics ApS.
As of August 8, 2025, Anders Vadsholt has left the board of directors of Blue Cell Therapeutics ApS.
As of August 7, 2025, Ole Vahlgren has left the board of directors of Blue Cell Therapeutics ApS.
Blue Cell Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -3,052,648, and the net result was DKK -15,189,850.
As of December 31, 2024, Sebastian Wehle has left the board of directors of Blue Cell Therapeutics ApS.
Blue Cell Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -741,530, and the net result was DKK -15,288,373.
As of April 11, 2024, Anders Vadsholt has joined the board of directors of Blue Cell Therapeutics ApS.
As of April 11, 2024, Sebastian Wehle has joined the board of directors of Blue Cell Therapeutics ApS.
As of October 20, 2023, Anella Rogaczewski has joined the board of directors of Blue Cell Therapeutics ApS.
As of August 24, 2023, Michael Ulveman has joined the board of directors of Blue Cell Therapeutics ApS.
As of August 24, 2023, Ole Vahlgren has joined the board of directors of Blue Cell Therapeutics ApS.
As of August 23, 2023, Michael Ulveman has left the board of directors of Blue Cell Therapeutics ApS.
As of August 23, 2023, Ole Vahlgren has left the board of directors of Blue Cell Therapeutics ApS.
Blue Cell Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK 852,135, and the net result was DKK -12,569,961.
As of January 30, 2023, Casper Tind Hansen has left the board of directors of Blue Cell Therapeutics ApS.
Blue Cell Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -843,696, and the net result was DKK -14,241,408.
As of February 3, 2022, André Rafal Rogaczewski has left the board of directors of Blue Cell Therapeutics ApS.
Blue Cell Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK -2,943,601, and the net result was DKK -14,026,899.
As of July 8, 2021, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of Blue Cell Therapeutics ApS.
As of June 23, 2021, Casper Tind Hansen has joined the board of directors of Blue Cell Therapeutics ApS.
As of June 23, 2021, Ole Vahlgren has joined the board of directors of Blue Cell Therapeutics ApS.
Blue Cell Therapeutics ApS has published its interim report for the period October 28, 2018 – December 31, 2019.
As of March 30, 2020, Michael Ulveman has joined the board of directors of Blue Cell Therapeutics ApS.
As of March 30, 2020, André Rafal Rogaczewski has joined the board of directors of Blue Cell Therapeutics ApS.
As of March 30, 2020, Thomas Tofte Hansen has left the board of directors of Blue Cell Therapeutics ApS.
As of March 30, 2020, Leif Helth Jensen has left the board of directors of Blue Cell Therapeutics ApS.
On March 30, 2020, the company changed its name from Regenerative Therapeutics IVS to Blue Cell Therapeutics ApS.
As of February 4, 2019, Thomas Tofte Hansen has joined the board of directors of Blue Cell Therapeutics ApS.
As of February 4, 2019, Søren Paludan Sheikh has joined the board of directors of Blue Cell Therapeutics ApS.
As of February 4, 2019, Leif Helth Jensen has joined the board of directors of Blue Cell Therapeutics ApS.
As of February 4, 2019, Søren Paludan Sheikh is registered as adm. dir. of Blue Cell Therapeutics ApS.
As of February 4, 2019, Thomas Tofte Hansen has stepped down as adm. dir. of Blue Cell Therapeutics ApS.
As of October 28, 2018, Thomas Tofte Hansen is registered as adm. dir. of Blue Cell Therapeutics ApS.
Blue Cell Therapeutics ApS was founded on October 28, 2018.
Companies in the same industry and area
CVR 36465972
CVR 45436497
CVR 46543912
CVR 44478587
CVR 31427169
